SaMD

The global workforce need the right tools as they continue to engage one of the greatest threats of our time with the resurgence of the coronavirus in China and marked increase in positive cases found in the US, says Joost Bruggeman, co-founder and CEO of Siilo.

A recently released analysis report from the Deloitte Center for Government Insights that examines the US’s current and proposed software as a medical device (SaMD) regulatory landscape, and includes suggestions on how the FDA’s pre-certification pilot program and other initiatives could better serve this fast-moving industry.